Fig. 1 Primary Endpoint Overall Survival, mITT




Fig. 2: Overall Survival: Subgroup Analyses 2, mITT




Fig. 3: OS in Concomitant Chemo-Radiotherapy, mITT




Fig. 4: OS in Sequential Chemo-Radiotherapy, mITT




Fig. 5: **Overall Survival by Concomitant/Sequential Chemo-Radiotherapy, mITT**




Fig. 6: **Overall Survival: Subgroup Analyses, mITT Concomitant vs Sequential Chemo-Radiotherapy 1**

a) Concomitant




Fig. 6: **Overall Survival: Subgroup Analyses, mITT Concomitant vs Sequential Chemo-Radiotherapy 1**

b) Sequential:




Fig. 7: **Overall Survival: Subgroup Analyses, mITT Concomitant vs Sequential Chemo-Radiotherapy 2**

a) Concomitant:




Fig. 7: **Overall Survival: Subgroup Analyses, mITT Concomitant vs Sequential Chemo-Radiotherapy 2**

b) Sequential:




Fig. 8: **Primary and Secondary Endpoints Concomitant vs Sequential Chemo-Radiotherapy**

	Concomitant n = 806			
	L-BLP25	Placebo	HR	95% CI
OS (months)	30.8	20.6	0.78	0.64 – 0.95
TTSP (months)	16.4	11.4	0.81	0.67 – 0.97
TTP (months)	11.9	9.4	0.85	0.71 – 1.02

	Sequential n = 433			
	L-BLP25	Placebo	HR	95% CI
OS (months)	19.4	24.6	1.12	0.87 – 1.44
TTSP (months)	12.3	11.4	0.92	0.73 – 1.17
TTP (months)	7.7	7.4	0.91	0.72 – 1.15

Fig. 9: Timing of Chemotherapy and Radiotherapy Relative to First Diagnosis, mITT




Fig. 10: Duration of Chemotherapy and Radiotherapy, mITT




Fig. 11: Study Design of L-BLP25 (EMR 63325-001) ("START")

